Citigroup reaffirmed their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Tuesday, MarketBeat.com reports. The firm currently has a $388.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $380.00.

Several other research analysts have also recently weighed in on REGN. Credit Suisse Group restated a buy rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Canaccord Genuity restated a buy rating and issued a $522.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Royal Bank of Canada started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 14th. They issued a sector perform rating and a $475.00 price objective on the stock. UBS Group decreased their price objective on shares of Regeneron Pharmaceuticals from $535.00 to $500.00 and set a buy rating on the stock in a research report on Thursday, September 21st. Finally, Oppenheimer restated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Hold and an average price target of $471.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at $366.96 on Tuesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The firm has a market cap of $39,565.49, a P/E ratio of 31.88, a P/E/G ratio of 1.41 and a beta of 1.53. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business earned $3.13 earnings per share. analysts anticipate that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of REGN. National Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.1% during the second quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock valued at $421,000 after purchasing an additional 26 shares during the period. Suntrust Banks Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.9% during the second quarter. Suntrust Banks Inc. now owns 3,194 shares of the biopharmaceutical company’s stock valued at $1,568,000 after purchasing an additional 59 shares during the period. Thrivent Financial For Lutherans boosted its stake in shares of Regeneron Pharmaceuticals by 2.2% during the second quarter. Thrivent Financial For Lutherans now owns 2,850 shares of the biopharmaceutical company’s stock valued at $1,400,000 after purchasing an additional 60 shares during the period. Raymond James Trust N.A. boosted its stake in shares of Regeneron Pharmaceuticals by 8.6% during the second quarter. Raymond James Trust N.A. now owns 899 shares of the biopharmaceutical company’s stock valued at $441,000 after purchasing an additional 71 shares during the period. Finally, Rafferty Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.9% during the second quarter. Rafferty Asset Management LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $1,528,000 after purchasing an additional 87 shares during the period. Institutional investors and hedge funds own 66.63% of the company’s stock.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/13/regeneron-pharmaceuticals-regn-neutral-rating-reiterated-at-citigroup.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.